| Alternative Name: | Von Hippel-Lindau tumor suppressor isoform 1 |
| |
| Clone: | AT82B10 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG2bκ |
| |
| Immunogen: | Recombinant human VHL (aa 1-154) purified from E. coli. |
| |
| UniProt ID: | P40337 |
| |
| Source: | Purified from ascites. |
| |
| Species reactivity: | Human
|
| |
| Applications: | ELISA, ICC, IF, WB
|
| |
| Purity Detail: | Protein A affinity purified |
| |
| Formulation: | Liquid. In PBS, pH 7.4, containing 0.02% sodium azide and 10% glycerol. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Von Hippel-Lindau disease (VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF). |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
